ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)

Shi, Jianhua; Cheng, Ying*; Wang, Qiming; Li, Kai; Wu, Lin; Han, Baohui; Chen, Gongyan; He, Jianxing; Wang, Jie; Qin, Haifeng; Li, Xiaoling广州医学院; 上海交通大学; 哈尔滨医科大学; 郑州大学; 中国医学科学院; 中国医学科学院北京协和医院; 1; 5; y
Frontiers of Medicine2022-10DOI: 10.1007/s11684-021-0916-8
5被引5阅读
引用收藏
分享

摘要

Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapies. This study aimed to investigate the efficacy and safety of anlotinib as third- or further-line therapy in patients with short-term relapsed SCLC from ALTER1202. Patients with short-term relapsed SCLC (disease progression within 3 months after completing > two lines of chemotherapy) in the anlotinib (n = 67) and placebo (n = 34) groups were analyzed. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival, objective response rate (ORR), disease control rate, and safety. Anlotinib significantly improved median PFS/OS (4.0 vs. 0.7 months, P < 0.0001)/(7.3 vs. 4.4 months, P = 0.006) compared with placebo. The ORR was 4.5%/2.9% in the anlotinib/placebo group (P = 1.000). The DCR in the anlotinib group was higher than that in the placebo group (73.1% vs. 11.8%, P < 0.001). The most common adverse events (AEs) were hypertension (38.8%), loss of appetite (28.4%), and fatigue (22.4%) in the anlotinib group and gammaglutamyl transpeptidase elevation (20.6%) in the placebo group. No grade 5 AEs occurred. For patients with short-term relapsed SCLC, third- or further-line anlotinib treatment was associated with improved survival benefit. Further studies are warranted in this regard.

学科与关键词

关键词
anlotinibchemotherapyshort-term relapsedsmall-cell lung cancer
相关
加载中…
  • Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial
    Cheng, Ying*; Wang, Qiming; Li, Kai; Shi, Jianhua; Wu, Lin; Han, Baohui; Chen, Gongyan; He, Jianxing; Wang, Jie; Qin, Haifeng; Li, XiaolingCancer Medicine, 2022, 11(4): 1081-1087.被引 9
  • The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Wang, Fen*; Jin, Feng; Cheng, Boran; Zhang, Yue; Zhou, Qing; Wang, ShubinJournal of Cancer Research and Clinical Oncology, 2022, 148(7): 1721-1735.被引 3
  • Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial
    Cheng, Y.; Yang, R.; Chen, J.; Zhang, W.; Xie, C.; Hu, Q.; Zhou, N.; Huang, C.; Wei, S.; Sun, H.; Li, X.; Yu, Y.; Lai, J.; Yang, H.; Fang, H.; Chen, H.; Zhang, P.; Gu, K.; Wang, Q.; Shi, J.; Yi, T.; Xu, X.; Ye, X.; Wang, D.; Xie, C.; Liu, C.; Zheng, Y.; Lin, D.; Zhuang, W.; Lu, P.; Yu, G.; Li, J.; Gu, Y.; Li, B.; Wu, R.; Jiang, O.; Wang, Z.; Wu, G.; Lin, H.; Zhong, D.; Xu, Y.; Shu, Y.; Wu, D.; Chen, X.; Wang, J.; Wang, M.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers of Medicine
发表日期
2022-10
卷期
第 16 卷, 第 5 期
页码
766-772
DOI
10.1007/s11684-021-0916-8
语言
ENGLISH
期刊收录
CSCD-C
期刊等级
3区
成果收录
SCIE
资助标注
Jilin Provincial Health and Family Planning Commission [2019J077]; Science and Technology Agency of Jilin Provincial Project [20200201518JC]; Chia-tai Tianqing Pharmaceutical Group Co., Ltd.

作者

  • S

    Shi, Jianhua (第一作者)

  • C

    Cheng, Ying (通讯)

查看全部 11 位作者收起作者
  • W

    Wang, Qiming

    zhengzhou univ

  • L

    Li, Kai

    tianjin med univ canc inst & hosp

  • W

    Wu, Lin

    hunan canc hosp

  • H

    Han, Baohui

    shanghai jiao tong univ

  • C

    Chen, Gongyan

    harbin med univ

  • H

    He, Jianxing

    1 · guangzhou med univ

  • W

    Wang, Jie

    chinese acad med sci · peking union med coll

  • Q

    Qin, Haifeng

    5 · chinese peoples liberat army gen hosp

  • L

    Li, Xiaoling

    liaoning canc hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417